- Home
- CCAP vs FDMT Comparison
CCAP vs FDMT Comparison
Compare CCAP & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCAP | FDMT |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 531.2M | 431.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CCAP | FDMT |
|---|---|---|
| Price | $14.59 | $7.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $16.50 | ★ $34.29 |
| AVG Volume (30 Days) | 253.8K | ★ 1.1M |
| Earning Date | 02-18-2026 | 02-27-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $172,891,000.00 | $120,000.00 |
| Revenue This Year | N/A | $21,227.03 |
| Revenue Next Year | N/A | $161.87 |
| P/E Ratio | $14.95 | ★ N/A |
| Revenue Growth | N/A | ★ 605.88 |
| 52 Week Low | $13.03 | $2.24 |
| 52 Week High | $20.19 | $12.34 |
Technical Indicators
Market Signals| Indicator | CCAP | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 41.70 |
| Support Level | $14.28 | $7.13 |
| Resistance Level | $14.93 | $8.80 |
| Average True Range (ATR) | 0.34 | 0.50 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 63.73 | 32.40 |
Price Performance
Historical ComparisonAbout CCAP Crescent Capital BDC Inc.
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.